Direvo pockets $17M in investment round

Germany's Direvo Biotech, a protein engineering company, has raised $16.8 million in its third round. Part of that money is being earmarked for its collaboration and research programs in therapeutic proteases and antibodies. A big group of investors participated in the round, including Danisco Venture A/S, Copenhagen, S-Equity Partner, Cologne, Mulligan BioCapital, Hamburg and funds managed by New York based Signet Healthcare Partners, as well as private investors such as Nobel laureate Prof. Manfred Eigen.

- see this release for more info

ALSO: Ikonisys has raised $30 million to advance its work in diagnostics. Release

Read more on: Venture capital news

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me